title: Letter from the editor.
authors.affiliation: Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel.
authors.forename: Ronald
authors.initials: R
authors.lastname: Ellis
authors.affiliation: Acquisitions Editor; Landes Bioscience; Vienna, Austria.
authors.forename: Eva M
authors.initials: EM
authors.lastname: Riedmann
mesh_terms: D001428:Bacterial Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000453:epidemiology / Q000517:prevention & control*; D017277:Drug Approval; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D016052:Protozoan Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D014765:Viral Vaccines / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D001428:Bacterial Vaccines; D016052:Protozoan Vaccines; D014765:Viral Vaccines